Literature DB >> 7847829

Improved engraftment of human tumours in SCID mice pretreated with radiation and anti-asialo GM1.

B Shpitz1, B J Fernandes, J B Mullen, J C Roder, S Gallinger.   

Abstract

The effects of sublethal radiation (3 Gy) and anti-asialo GM1 (anti-ASGM1) on engraftment of human tumour cell lines and fresh tumour were evaluated in the severe combined immunodeficient (SCID) mouse. Four tumour cell lines (colonic adenocarcinoma LS174T, malignant melanoma MEWO, lung adenocarcinoma H125, chronic myelogenous leukemia K562) and a fresh colon cancer metastasis were injected subcutaneously, intraperitoneally or intravenously into SCID mice. Tumour volume and metastatic spread of implanted tumours were evaluated 3-8 weeks following inoculation. Pretreatment with radiation and anti-ASGM1 resulted in more rapid and extensive uptake of subcutaneous and intraperitoneal tumours. Tail vein injection into pretreated animals also resulted in a greater number of lung metastases of H125, MEWO and K562 cell lines. This study demonstrates that sublethal radiation and the elimination of murine NK cell activity with anti-ASGM1 improves tumour take rates. These findings should prove useful for investigations of human cancer immunotherapy using SCID mice engrafted with human lymphocytes and human tumours.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7847829

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  2 in total

1.  Circulating blood monocytes traffic to and participate in the periprosthetic tissue inflammation.

Authors:  Kai Zhang; Tang-Hong Jia; David McQueen; Wei-Ming Gong; David C Markel; Paul H Wooley; Shang-You Yang
Journal:  Inflamm Res       Date:  2009-05-30       Impact factor: 4.575

2.  Anti-CD7 antibody and immunotoxin treatment of human CD7(+)T-cell leukaemia is significantly less effective in NOD/LtSz-scid mice than in CB.17 scid mice.

Authors:  D J Flavell; S L Warnes; A L Noss; S U Flavell
Journal:  Br J Cancer       Date:  2000-12       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.